glp-1 and ckd kidney disease glp-1 kidney disease Brasil Unlocking Cardio-Renal Protection: Breakthrough with

Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide

By measuring changes in these marks, the team could assess whether the treatment was associated with a slower or faster biological aging pattern

Constipation can happen during GLP-1 therapy because appetite, fluid intake, fiber intake, movement, and digestion may all change

They are used, when appropriate, within a broader GLP-1 Weight Loss for Longevity framework that emphasizes body composition, metabolic health, protein adequacy, resistance training, cardiovascular risk reduction, and long-term maintenance

Studies of tirzepatide (Zepbound and Mounjaro) have found similar patterns

Unlike semaglutide, which targets only the GLP-1 receptor, tirzepatide is a dual-action medication that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors